Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Dyne Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get DYN alerts

About Douglas Kerr

The proxy statement of Dyne Therapeutics, Inc. reports total compensation of $1,057,598 for Douglas Kerr in fiscal 2025, including a base salary of $537,000. Disclosed compensation is on record for 2 fiscal years. Dyne Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Dyne Therapeutics, Inc. includes John G. Cox (CEO and Board Member), Josh Brumm (CEO), Erick Lucera (CFO and Chief Accounting Officer) and 4 others.

Affiliation history

Company network

Leadership on record at Dyne Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Dyne Therapeutics, Inc. (DYN) $537,000 $1,057,598
2024 Dyne Therapeutics, Inc. (DYN) $172,795 $7,741,647

Recent activity

No call appearances or filed executive changes recorded yet.